IRIS Accounts Production v26.3.0.614 13533476 Board of Directors 1.4.25 31.3.26 31.3.26 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh135334762025-03-31135334762026-03-31135334762025-04-012026-03-31135334762024-03-31135334762024-04-012025-03-31135334762025-03-3113533476ns15:EnglandWales2025-04-012026-03-3113533476ns14:PoundSterling2025-04-012026-03-3113533476ns10:Director12025-04-012026-03-3113533476ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3113533476ns10:SmallEntities2025-04-012026-03-3113533476ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3113533476ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3113533476ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3113533476ns10:FullAccounts2025-04-012026-03-311353347612025-04-012026-03-3113533476ns10:Director22025-04-012026-03-3113533476ns10:RegisteredOffice2025-04-012026-03-3113533476ns5:CurrentFinancialInstruments2026-03-3113533476ns5:CurrentFinancialInstruments2025-03-3113533476ns5:ShareCapital2026-03-3113533476ns5:ShareCapital2025-03-3113533476ns5:RetainedEarningsAccumulatedLosses2026-03-3113533476ns5:RetainedEarningsAccumulatedLosses2025-03-3113533476ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3113533476ns5:IntangibleAssetsOtherThanGoodwill2025-03-3113533476ns5:IntangibleAssetsOtherThanGoodwill2026-03-3113533476ns5:IntangibleAssetsOtherThanGoodwill2025-03-3113533476ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3113533476ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-31
REGISTERED NUMBER: 13533476 (England and Wales)









NEUROCHASE INNOVATIONS LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026






NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


NEUROCHASE INNOVATIONS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2026







DIRECTORS: Prof S S Gill
Mrs S Kane





REGISTERED OFFICE: St Brandon's House
29 Great George Street
Bristol
BS1 5QT





REGISTERED NUMBER: 13533476 (England and Wales)






NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

BALANCE SHEET
31 MARCH 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 164,766 91,349

CURRENT ASSETS
Debtors 5 17,619 2,929
Cash at bank and in hand 13,147 2,323
30,766 5,252
CREDITORS
Amounts falling due within one year 6 258,957 158,298
NET CURRENT LIABILITIES (228,191 ) (153,046 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(63,425

)

(61,697

)

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings (63,525 ) (61,797 )
SHAREHOLDERS' FUNDS (63,425 ) (61,697 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

BALANCE SHEET - continued
31 MARCH 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 October 2026 and were signed on its behalf by:





Mrs S Kane - Director


NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1. STATUTORY INFORMATION

Neurochase Innovations Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
The financial statements have been prepared on the going concern basis, which assumes that the company will continue in operational existence for the foreseeable future.

In assessing the appropriateness of the going concern basis, the directors have reviewed the company's financial position, forecast cash flows and anticipated funding requirements for a period of at least twelve months from the date of approval of these financial statements.

The company is reliant on continued financial support from its parent company, Neurochase Holdings Limited, to fund its ongoing operations and development activities. The directors, who are also directors of Neurochase Holdings Limited, have considered the Group's available resources, forecast expenditure and expected funding requirements, and intend that financial support will continue to be made available to the company for the foreseeable future to enable it to meet its liabilities as they fall due.

Based on this assessment, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for a period of at least twelve months from the date of approval of these financial statements. Accordingly, the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Royalty income
Royalty revenue is recognised on an accruals basis in accordance with the terms of the relevant agreement (provided that it is probable that the economic benefits will flow to the company and the amount of revenue can be measured reliably). Royalties determined on a time basis are recognised on a straight-line basis over the period of the agreement. Royalty arrangements that are based on production, sales and other measures are recognised by reference to the underlying arrangement.

NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026

2. ACCOUNTING POLICIES - continued

Significant judgements and estimates
In the application of the company's accounting policies, which are described in note 2, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less accumulated amortisation and any accumulated impairment losses.
Intangible assets relate to patent costs in respect of intellectual property held by the company.

Capitalised patent costs are yet to be amortised and will commence once the product has been fully developed and marketed.

Cash & cash equivalents
Cash and cash equivalents are basic financial instruments and include cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments
The company has elected to apply the provisions of Section 11 "Basic Financial Instruments".
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Basic financial liabilities
Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.


NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 3 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 April 2025 91,349
Additions 73,417
At 31 March 2026 164,766
NET BOOK VALUE
At 31 March 2026 164,766
At 31 March 2025 91,349

Intangible assets relate to patent costs in respect of intellectual property held by the company.

NEUROCHASE INNOVATIONS LTD (REGISTERED NUMBER: 13533476)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Other debtors 17,619 2,929

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade creditors 10,735 -
Amounts owed to group
undertakings 246,622 156,622
Accrued expenses 1,600 1,676
258,957 158,298

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2026 2025
Value: £ £
100 Ordinary shares £1 100 100
100 100

8. RELATED PARTY DISCLOSURES

The company has taken advantage of the exemption under paragraph 33.1A of FRS 102 from disclosing transactions with wholly-owned members of the group.

9. PARENT UNDERTAKING AND ULTIMATE CONTROLLING PARTY

The company's immediate parent undertaking is Neurochase Holdings Limited. The ultimate controlling party is Professor Steven Gill, by virtue of his majority shareholding in Neurochase Holdings Limited.